XML 93 R77.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | $ 109,871 | $ 87,821 | $ 45,212
ZIOPHARM Oncology, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 33,836 | 19,306 | 14,621
Oragenics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 2,752 | 6,535 | 1,643
Fibrocell Science, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 5,942 | 12,179 | 6,192
Genopaver, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 6,117 | 3,829 | 1,783
S & I Ophthalmic, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 6,141 | 4,115 | 2,832
OvaXon, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 2,934 | 2,540 | 2,799
Intrexon Energy Partners, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 17,552 | 13,447 | 6,102
Persea Bio, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,278 | 1,241 |
Ares Trading S.A. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 10,192 | 4,728 |
Thrive Agrobiotics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,714 | 266 |
Intrexon Energy Partners II, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 3,169 | 167 |
Exotech Bio, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 792 |  |
Relieve Genetics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,239 |  |
Intrexon T1D Partners, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,908 |  |
AD Skincare, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 695 |  |
Genten Therapeutics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 386 |  |
CRS Bio, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 148 |  |
Other |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 13,076 | 19,468 | 9,240
Upfront and Milestone Payments |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 34,433 | 32,513 | 9,625
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 11,529 | 2,855 | 2,577
Upfront and Milestone Payments | Oragenics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,047 | 5,679 | 1,045
Upfront and Milestone Payments | Fibrocell Science, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 2,419 | 6,046 | 1,794
Upfront and Milestone Payments | Genopaver, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 273 | 273 | 273
Upfront and Milestone Payments | S & I Ophthalmic, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 0 | 0 | 0
Upfront and Milestone Payments | OvaXon, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 0 | 0 | 0
Upfront and Milestone Payments | Intrexon Energy Partners, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 2,500 | 2,500 | 1,875
Upfront and Milestone Payments | Persea Bio, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 500 | 500 |
Upfront and Milestone Payments | Ares Trading S.A. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 6,389 | 3,933 |
Upfront and Milestone Payments | Thrive Agrobiotics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 185 | 46 |
Upfront and Milestone Payments | Intrexon Energy Partners II, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 2,000 | 167 |
Upfront and Milestone Payments | Exotech Bio, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 417 |  |
Upfront and Milestone Payments | Relieve Genetics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 361 |  |
Upfront and Milestone Payments | Intrexon T1D Partners, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 821 |  |
Upfront and Milestone Payments | AD Skincare, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 241 |  |
Upfront and Milestone Payments | Genten Therapeutics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 122 |  |
Upfront and Milestone Payments | CRS Bio, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 57 |  |
Upfront and Milestone Payments | Other |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 5,572 | 10,514 | 2,061
Research and Development Services |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 75,438 | 55,308 | 35,587
Research and Development Services | ZIOPHARM Oncology, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 22,307 | 16,451 | 12,044
Research and Development Services | Oragenics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,705 | 856 | 598
Research and Development Services | Fibrocell Science, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 3,523 | 6,133 | 4,398
Research and Development Services | Genopaver, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 5,844 | 3,556 | 1,510
Research and Development Services | S & I Ophthalmic, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 6,141 | 4,115 | 2,832
Research and Development Services | OvaXon, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 2,934 | 2,540 | 2,799
Research and Development Services | Intrexon Energy Partners, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 15,052 | 10,947 | 4,227
Research and Development Services | Persea Bio, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 778 | 741 |
Research and Development Services | Ares Trading S.A. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 3,803 | 795 |
Research and Development Services | Thrive Agrobiotics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,529 | 220 |
Research and Development Services | Intrexon Energy Partners II, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,169 | 0 |
Research and Development Services | Exotech Bio, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 375 |  |
Research and Development Services | Relieve Genetics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 878 |  |
Research and Development Services | Intrexon T1D Partners, LLC |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 1,087 |  |
Research and Development Services | AD Skincare, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 454 |  |
Research and Development Services | Genten Therapeutics, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 264 |  |
Research and Development Services | CRS Bio, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | 91 |  |
Research and Development Services | Other |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Collaboration and licensing revenues | $ 7,504 | $ 8,954 | $ 7,179

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use as well as revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration and licensing agreements. + References No definition available. + Details
Name: | xon_CollaborationAndLicensingRevenue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GenopaverLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_SIOphthalmicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OvaXonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_PerseaBioLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_AresTradingS.A.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ThriveAgrobioticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersIILLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ExotechBioInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_RelieveGeneticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonT1DPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ADSkincareInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GentenTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_CRSBioInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OtherCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |